» Articles » PMID: 32239011

Formulation of Thrombin-inhibiting Hydrogels Via Self-assembly of Ionic Peptides with Peptide-modified Polymers

Overview
Journal Soft Matter
Specialties Biochemistry
Chemistry
Date 2020 Apr 3
PMID 32239011
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Cell therapy for spinal cord injuries offers the possibility of replacing lost cells after trauma to the central nervous system (CNS). In preclinical studies, synthetic hydrogels are often co-delivered to the injury site to support survival and integration of the transplanted cells. These hydrogels ideally mimic the mechanical and biochemical features of a healthy CNS extracellular matrix while also providing the possibility of localized drug delivery to promote healing. In this work, we synthesize peptide-functionalized polymers that contain both a peptide sequence for incorporation into self-assembled peptide hydrogels along with bioactive peptides that inhibit scar formation. We demonstrate that peptide hydrogels formulated with the peptide-functionalized polymers possess similar mechanical properties (soft and shear-thinning) as peptide-only hydrogels. Small angle neutron scattering analysis reveals that polymer-containing hydrogels possess larger inhomogeneous domains but small-scale features such as mesh size remain the same as peptide-only hydrogels. We further confirm that the integrated hydrogels containing bioactive peptides exhibit thrombin inhibition activity, which has previously shown to reduce scar formation in vivo. Finally, while the survival of encapsulated cells was poor, cells cultured on the hydrogels exhibited good viability. Overall, the described composite hydrogels formed from self-assembling peptides and peptide-modified polymers are promising, user-friendly materials for CNS applications in regeneration.

Citing Articles

Recent Progress in the Design and Medical Application of In Situ Self-Assembled Polypeptide Materials.

Wang T, Xia Y, Gao J, Xu D, Han M Pharmaceutics. 2021; 13(5).

PMID: 34069645 PMC: 8160760. DOI: 10.3390/pharmaceutics13050753.

References
1.
Warkentin T, Greinacher A, Koster A . Bivalirudin. Thromb Haemost. 2008; 99(5):830-9. DOI: 10.1160/TH07-10-0644. View

2.
Jazayeri S, Beygi S, Shokraneh F, Hagen E, Rahimi-Movaghar V . Incidence of traumatic spinal cord injury worldwide: a systematic review. Eur Spine J. 2014; 24(5):905-18. DOI: 10.1007/s00586-014-3424-6. View

3.
Baumann M, Kang C, Tator C, Shoichet M . Intrathecal delivery of a polymeric nanocomposite hydrogel after spinal cord injury. Biomaterials. 2010; 31(30):7631-9. DOI: 10.1016/j.biomaterials.2010.07.004. View

4.
Assinck P, Duncan G, Hilton B, Plemel J, Tetzlaff W . Cell transplantation therapy for spinal cord injury. Nat Neurosci. 2017; 20(5):637-647. DOI: 10.1038/nn.4541. View

5.
Jain A, Kim Y, McKeon R, Bellamkonda R . In situ gelling hydrogels for conformal repair of spinal cord defects, and local delivery of BDNF after spinal cord injury. Biomaterials. 2005; 27(3):497-504. DOI: 10.1016/j.biomaterials.2005.07.008. View